Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 12/20 | 0.34 |
| ▸ | MMP9 | P14780 | 8/20 | 0.34 |
| ▸ | MMP3 | P08254 | 8/20 | 0.34 |
| ▸ | MMP13 | P45452 | 7/20 | 0.34 |
| ▸ | MMP1 | P03956 | 10/20 | 0.33 |
| ▸ | MMP8 | P22894 | 5/20 | 0.33 |
| ▸ | MMP7 | P09237 | 2/20 | 0.33 |
| ▸ | MMP14 | P50281 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940892 | 0.84 | PLA2G7 (0.40) | PLA2G7MMP2MMP9MMP3MMP13 | |
| SCHEMBL6945464 | 0.77 | PLA2G7 (0.49) | PLA2G7MMP2MMP9MMP3MMP13 | |
| SCHEMBL5036973 | 0.75 | PLA2G7 (0.46) | PLA2G7MMP2MMP9MMP3MMP13 | |
| SCHEMBL4827863 | 0.74 | PLA2G7 (0.46) | PLA2G7MMP2MMP9MMP3MMP13 | |
| SCHEMBL422413 | 0.74 | PLA2G7 (0.49) | PLA2G7MMP2MMP9MMP3MMP13 | |
| SCHEMBL1593903 | 0.73 | PLA2G7 (0.45) | PLA2G7MMP2MMP9MMP3MMP13 | |
| SCHEMBL7040815 | 0.71 | PLA2G7 (0.50) | PLA2G7MMP2MMP9MMP3MMP13 | |
| SCHEMBL7518193 | 0.71 | PLA2G7 (0.50) | PLA2G7MMP2MMP9MMP3MMP13 | |
| SCHEMBL14009878 | 0.71 | PLA2G7 (0.42) | PLA2G7MMP2MMP9MMP3MMP13 | |
| SCHEMBL4756856 | 0.71 | KMT2A (0.56) | PLA2G7MMP2MMP9MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001930-B1 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| US-6235786-B1 | RHEUMATIC DISORDERS; BONE DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS | ABBOTT LABORATORIES | 2001-05-22 | — | — | US | disclosed |
| EP-1001930-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Abbott Laboratories (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006361-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | PLA2G7 267/4885MMP2 4/4885MMP9 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.